Your browser doesn't support javascript.
loading
N- and s-substituted Pyrazolopyrimidines: A promising new class of potent c-Src kinase inhibitors with prominent antitumor activity.
Awaji, Aeshah A; Zaloa, Waheed Ali Zaki El; Seleem, Mohamed A; Alswah, Mohamed; Elsebaei, Mohamed M; Bayoumi, Ashraf H; El-Morsy, Ahmed M; Alfaifi, Mohammad Y; Shati, Ali A; Elbehairi, Serag Eldin I; Almaghrabi, Mohammed; Aljohani, Ahmed K B; Ahmed, Hany E A.
Affiliation
  • Awaji AA; Department of Biology, Faculty of Science, University College of Taymaa, University of Tabuk, Tabuk 71491, Saudi Arabia.
  • Zaloa WAZE; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
  • Seleem MA; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
  • Alswah M; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt. Electronic address: drmohammedalswah@azhar.edu.eg.
  • Elsebaei MM; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt. Electronic address: m.elsebaei@azhar.edu.eg.
  • Bayoumi AH; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
  • El-Morsy AM; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt; Pharmaceutical Chemistry Department, College of Pharmacy, The Islamic University, Najaf 54001, Iraq.
  • Alfaifi MY; Biology Department, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia.
  • Shati AA; Biology Department, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia.
  • Elbehairi SEI; Biology Department, Faculty of Science, King Khalid University, Abha 9004, Saudi Arabia; Cell Culture Lab, Egyptian Organization for Biological Products and Vaccines (VACSERA Holding Company), 51 Wezaret El-Zeraa St., Agouza, Giza, Egypt. Electronic address: serag@kku.edu.sa.
  • Almaghrabi M; Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah 41477, Saudi Arabia.
  • Aljohani AKB; Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah 41477, Saudi Arabia.
  • Ahmed HEA; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
Bioorg Chem ; 145: 107228, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38422592
ABSTRACT
In this work, readily achievable synthetic pathways were utilized for construction of a library of N/S analogues based on the pyrazolopyrimidine scaffold with terminal alkyl or aryl fragments. Subsequently, we evaluated the anticancer effects of these novel analogs against the proliferation of various cancer cell lines, including breast, colon, and liver lines. The results were striking, most of the tested molecules exhibited strong and selective cytotoxic activity against the MDA-MB-231 cancer cell line; IC50 1.13 µM. Structure-activity relationship (SAR) analysis revealed that N-substituted derivatives generally enhanced the cytotoxic effect, particularly with aliphatic side chains that facilitated favorable target interactions. We also investigated apoptosis, DNA fragmentation, invasion assay, and anti-migration effects, and discussed their underlying molecular mechanisms for the most active compound 7c. We demonstrated that 7c N-propyl analogue could inhibit MDA-MB-231 TNBC cell proliferation by inducing apoptosis through the regulation of vital proteins, namely c-Src, p53, and Bax. In addition, our results also revealed the potential of these compounds against tumor metastasis by downregulating the invasion and migration modes. Moreover, the in vitro inhibitory effect of active analogs against c-Src kinase was studied and proved that might be the main cause of their antiproliferative effect. Overall, these compelling results point towards the therapeutic potential of these derivatives, particularly those with N-substitution as promising candidates for the treatment of TNBC type of breast cancer.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Triple Negative Breast Neoplasms / Antineoplastic Agents Limits: Humans Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Triple Negative Breast Neoplasms / Antineoplastic Agents Limits: Humans Language: En Year: 2024 Type: Article